HER 2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization.
Loading...
Date
2012-04
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Introduction : HER2/neu gene status in breast cancers can be evaluated by targeting protein and gene - immunohistochemistry (IHC) and fluorescence in-situ hybridization (FISH). Recent studies have shown chromogenic in-situ hybridization (CISH) as a relatively cheaper alternative. Materials and Methods : Forty-three nonconsecutive, randomly selected primary invasive breast cancer cases were evaluated for c-erbB-2 (HER2 protein) by IHC and gene amplification by FISH and CISH. Results of each of the same were compared. Results : CISH showed approximately 90% and 100% concordance for IHC negative and positive cases, respectively; while approximately 94.4% and 91% concordance with FISH amplified and non-amplified cases, respectively. Conclusion : This study showed feasibility of incorporation of CISH as a low cost option in routine management of breast carcinoma in the Indian setting. Secondly, reconfirmation of IHC negative and positive cases can be done by CISH.
Description
Keywords
Breast cancer, chromogenic in-situ hybridization, fluorescence in-situ hybridization, HER2/neu, immunohistochemistry
Citation
Shirsat Hemlata S, Epari Sridhar, Shet Tanuja, Bagal Rajani, Hawaldar Rohini, Desai Sangeeta B. HER 2 status in invasive breast cancer: Immunohistochemistry, fluorescence in-situ hybridization and chromogenic in-situ hybridization. Indian Journal of Pathology & Microbiology. 2012 Apr-Jun 55(2): 175-179.